Sailong Pharmaceutical Group Co (SZSE:002898) ROCE % : -2.28% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Sailong Pharmaceutical Group Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sailong Pharmaceutical Group Co's annualized ROCE % for the quarter that ended in Sep. 2024 was -2.28%.

Sailong Pharmaceutical Group Co ROCE % Historical Data

The historical data trend for Sailong Pharmaceutical Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sailong Pharmaceutical Group Co ROCE % Chart

Sailong Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

5.07

-6.70

-1.16

-3.70

5.14

Sailong Pharmaceutical Group Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															3.56	8.95	2.48	1.19	-2.28

Sailong Pharmaceutical Group Co ROCE % Calculation

Sailong Pharmaceutical Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	29.264	/	( ( (848.015 - 296.451)	+	(813.844 - 227.01) )	/ 2 )
	=	29.264	/	( (551.564	+	586.834)	/ 2 )
	=	29.264	/	569.199
	=	5.14 %

Sailong Pharmaceutical Group Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-13.332	/	( ( (796.479 - 217.954)	+	(841.078 - 249.034) )	/ 2 )
	=	-13.332	/	( ( 578.525	+	592.044 )	/ 2 )
	=	-13.332	/	585.2845
	=	-2.28 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Sailong Pharmaceutical Group Co (SZSE:002898) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sailong Pharmaceutical Group Co ROCE % Related Terms

Thank you for viewing the detailed overview of Sailong Pharmaceutical Group Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sailong Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sailong Pharmaceutical Group Co Ltd (SZSE:002898) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 47, Haibin South Road, 2nd Floor, Everbright International Trade Center, Guangdong Province, Zhuhai, CHN, 519015

Website

http://www.sailong.cn

Sailong Pharmaceutical Group Co Ltd is a pharmaceutical company. It is mainly engaged in the development, production, marketing and technical services of pharmaceuticals. The company's products are mainly concentrated in the fields of the nervous system, cardiovascular and digestive system. The product range includes monosialin tetrahexose ganglioside sodium injections, brain protein hydrolyzate for injections, clindamycin phosphate for injections, pantoprazole sodium for injections and milrinon injections, among others.

Executives

Tang Lin	Director
Long Zhi Xiang	Director
Deng Yong Jun	Supervisors
Zhou Bei	Supervisors
Li Jian Feng	Directors, executives

Sailong Pharmaceutical Group Co Headlines

No Headlines